Arcutis Biotherapeutics Inc (NASDAQ: ARQT)’s stock price has soared by 6.41 in relation to previous closing price of 14.71. Nevertheless, the company has seen a gain of 10.23% in its stock price over the last five trading days. globenewswire.com reported 2025-01-06 that WESTLAKE VILLAGE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 75,500 restricted stock units of Arcutis’ common stock to eight newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of January 2, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
Is It Worth Investing in Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Right Now?
The 36-month beta value for ARQT is also noteworthy at 1.30. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for ARQT is 102.97M, and at present, short sellers hold a 22.44% of that float. The average trading volume of ARQT on January 07, 2025 was 2.03M shares.
ARQT’s Market Performance
ARQT’s stock has seen a 10.23% increase for the week, with a 27.16% rise in the past month and a 59.89% gain in the past quarter. The volatility ratio for the week is 5.61%, and the volatility levels for the past 30 days are at 7.74% for Arcutis Biotherapeutics Inc The simple moving average for the last 20 days is 11.32% for ARQT’s stock, with a simple moving average of 55.78% for the last 200 days.
Analysts’ Opinion of ARQT
Many brokerage firms have already submitted their reports for ARQT stocks, with H.C. Wainwright repeating the rating for ARQT by listing it as a “Buy.” The predicted price for ARQT in the upcoming period, according to H.C. Wainwright is $19 based on the research report published on December 30, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see ARQT reach a price target of $15. The rating they have provided for ARQT stocks is “Buy” according to the report published on August 28th, 2024.
Mizuho gave a rating of “Buy” to ARQT, setting the target price at $8 in the report published on January 03rd of the previous year.
ARQT Trading at 32.31% from the 50-Day Moving Average
After a stumble in the market that brought ARQT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.87% of loss for the given period.
Volatility was left at 7.74%, however, over the last 30 days, the volatility rate increased by 5.61%, as shares surge +25.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +85.08% upper at present.
During the last 5 trading sessions, ARQT rose by +9.61%, which changed the moving average for the period of 200-days by +52.90% in comparison to the 20-day moving average, which settled at $14.06. In addition, Arcutis Biotherapeutics Inc saw 12.37% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARQT starting from Welgus Howard G., who sale 10,000 shares at the price of $14.67 back on Jan 02 ’25. After this action, Welgus Howard G. now owns 151,944 shares of Arcutis Biotherapeutics Inc, valued at $146,714 using the latest closing price.
Welgus Howard G., the Director of Arcutis Biotherapeutics Inc, proposed sale 10,000 shares at $14.67 during a trade that took place back on Jan 02 ’25, which means that Welgus Howard G. is holding shares at $146,714 based on the most recent closing price.
Stock Fundamentals for ARQT
Current profitability levels for the company are sitting at:
- -1.31 for the present operating margin
- 0.89 for the gross margin
The net margin for Arcutis Biotherapeutics Inc stands at -1.41. The total capital return value is set at -0.69. Equity return is now at value -192.31, with -53.55 for asset returns.
Based on Arcutis Biotherapeutics Inc (ARQT), the company’s capital structure generated 0.57 points at debt to capital in total, while cash flow to debt ratio is standing at -0.82. The debt to equity ratio resting at 1.31. The interest coverage ratio of the stock is -6.19.
Currently, EBITDA for the company is -227.43 million with net debt to EBITDA at -0.45. When we switch over and look at the enterprise to sales, we see a ratio of 13.71. The receivables turnover for the company is 2.31for trailing twelve months and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.46.
Conclusion
In summary, Arcutis Biotherapeutics Inc (ARQT) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
